MaxCyte Statistics
Total Valuation
MaxCyte has a market cap or net worth of $168.54 million. The enterprise value is $80.98 million.
Important Dates
The last earnings date was Wednesday, November 12, 2025, after market close.
| Earnings Date | Nov 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
MaxCyte has 106.67 million shares outstanding. The number of shares has increased by 1.67% in one year.
| Current Share Class | 106.67M |
| Shares Outstanding | 106.67M |
| Shares Change (YoY) | +1.67% |
| Shares Change (QoQ) | +0.20% |
| Owned by Insiders (%) | 1.41% |
| Owned by Institutions (%) | 67.06% |
| Float | 96.94M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.87 |
| Forward PS | 4.52 |
| PB Ratio | 0.93 |
| P/TBV Ratio | 0.96 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.35 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.74, with a Debt / Equity ratio of 0.10.
| Current Ratio | 7.74 |
| Quick Ratio | 7.08 |
| Debt / Equity | 0.10 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -23.19% and return on invested capital (ROIC) is -14.68%.
| Return on Equity (ROE) | -23.19% |
| Return on Assets (ROA) | -13.66% |
| Return on Invested Capital (ROIC) | -14.68% |
| Return on Capital Employed (ROCE) | -25.59% |
| Revenue Per Employee | $301,921 |
| Profits Per Employee | -$400,272 |
| Employee Count | 114 |
| Asset Turnover | 0.15 |
| Inventory Turnover | 0.77 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -55.49% in the last 52 weeks. The beta is 0.33, so MaxCyte's price volatility has been lower than the market average.
| Beta (5Y) | 0.33 |
| 52-Week Price Change | -55.49% |
| 50-Day Moving Average | 1.58 |
| 200-Day Moving Average | 2.31 |
| Relative Strength Index (RSI) | 50.59 |
| Average Volume (20 Days) | 652,179 |
Short Selling Information
The latest short interest is 3.03 million, so 2.84% of the outstanding shares have been sold short.
| Short Interest | 3.03M |
| Short Previous Month | 3.43M |
| Short % of Shares Out | 2.84% |
| Short % of Float | 3.12% |
| Short Ratio (days to cover) | 5.02 |
Income Statement
In the last 12 months, MaxCyte had revenue of $34.42 million and -$45.63 million in losses. Loss per share was -$0.43.
| Revenue | 34.42M |
| Gross Profit | 27.53M |
| Operating Income | -50.51M |
| Pretax Income | -45.63M |
| Net Income | -45.63M |
| EBITDA | -46.21M |
| EBIT | -50.51M |
| Loss Per Share | -$0.43 |
Full Income StatementBalance Sheet
The company has $105.73 million in cash and $18.16 million in debt, giving a net cash position of $87.57 million or $0.82 per share.
| Cash & Cash Equivalents | 105.73M |
| Total Debt | 18.16M |
| Net Cash | 87.57M |
| Net Cash Per Share | $0.82 |
| Equity (Book Value) | 180.28M |
| Book Value Per Share | 1.69 |
| Working Capital | 108.54M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$39.54 million and capital expenditures -$1.68 million, giving a free cash flow of -$41.23 million.
| Operating Cash Flow | -39.54M |
| Capital Expenditures | -1.68M |
| Free Cash Flow | -41.23M |
| FCF Per Share | -$0.39 |
Full Cash Flow StatementMargins
Gross margin is 79.97%, with operating and profit margins of -146.76% and -132.58%.
| Gross Margin | 79.97% |
| Operating Margin | -146.76% |
| Pretax Margin | -132.58% |
| Profit Margin | -132.58% |
| EBITDA Margin | -134.25% |
| EBIT Margin | -146.76% |
| FCF Margin | n/a |
Dividends & Yields
MaxCyte does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.67% |
| Shareholder Yield | -1.67% |
| Earnings Yield | -27.07% |
| FCF Yield | -24.46% |
Analyst Forecast
The average price target for MaxCyte is $7.50, which is 374.68% higher than the current price. The consensus rating is "Buy".
| Price Target | $7.50 |
| Price Target Difference | 374.68% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | 23.18% |
| EPS Growth Forecast (5Y) | -22.12% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
MaxCyte has an Altman Z-Score of 4 and a Piotroski F-Score of 1.
| Altman Z-Score | 4 |
| Piotroski F-Score | 1 |
